Jak Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib

September 2025 in “ Acta Dermato Venereologica ”

Federica Li Pomi, Mario Vaccaro, Maria Giuseppa Vitale, Roberta Alaimo, Francesco Borgia

JAK inhibitors baricitinib alopecia areata vitiligo autoimmune conditions

From the encyclopedia

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study investigates the effects of the JAK inhibitor baricitinib on individuals with Down syndrome, focusing on its impact on alopecia areata and vitiligo. The findings suggest that baricitinib can lead to the resolution of alopecia areata and improvement in vitiligo symptoms in this population. This research highlights the potential of JAK inhibitors as a therapeutic option for managing autoimmune conditions associated with Down syndrome.

View this study on medicaljournalssweden.se →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research JAK Inhibition Decreases the Autoimmune Burden in Down Syndrome

18 citations , August 2024 in “eLife”

This study investigated immune dysregulation in individuals with Down syndrome and found that treatment with the JAK inhibitor tofacitinib improved skin conditions like alopecia areata and reduced autoimmune markers without severe side effects. Additional research is necessary to understand its broader impacts.

research Down Syndrome and Autoimmune Disease

14 citations , June 2024 in “Clinical Reviews in Allergy & Immunology”

This review highlights a higher prevalence of autoimmune disorders such as thyroid disease, celiac disease, alopecia areata, and vitiligo among individuals with Down syndrome compared to the neurotypical population, suggesting intrinsic immune dysregulation linked to chromosome 21.

research Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences

April 2024 in “International journal of molecular sciences”

This study examines the similarities and differences in the pathogenesis of autoimmune conditions alopecia areata and vitiligo, highlighting shared features like immune cell involvement and cytokine pathways, while noting differing immune responses in skin and hair.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management

290 citations , August 2021 in “Clinical Reviews in Allergy & Immunology”

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata

32 citations , April 2019 in “JAAD case reports”

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.